Regulatory Milestones Fail to Lift Johnson & Johnson Shares

Despite securing two significant regulatory approvals from the U.S. Food and Drug Administration (FDA) in early March 2026, shares of healthcare giant Johnson & Johnson closed lower, highlighting investor concerns that extend beyond pipeline developments. The stock declined 2.31% on March 5, finishing the trading session at $239.63.

A Week of Regulatory Progress

The more recent FDA action granted clearance for a novel combination treatment targeting multiple myeloma. The therapy, which pairs TECVAYLI with DARZALEX FASPRO, is now approved for use in patients with relapsed or refractory forms of the blood cancer. Crucially, this authorization allows the drugs to be administered at earlier stages of treatment than previously permitted. Clinical evidence supporting the approval demonstrated benefits in both progression-free and overall survival rates.

This decision followed another positive regulatory step just 48 hours earlier. On March 3, 2026, the FDA awarded Fast Track designation to the company’s immunology candidate, Nipocalimab. This status is intended to expedite the development and review process for the drug, which is being studied as a treatment for systemic lupus erythematosus. The autoimmune condition is estimated to affect between 3 and 5 million people globally.

Market Reaction Tempered by Competitive and Legal Pressures

The market’s muted response to these pipeline advancements is attributed to several concurrent challenges. Significant competitive pressure emerged from United Therapeutics, which released positive Phase 3 trial data for Ralinepag. This drug is a direct competitor to Johnson & Johnson’s established pulmonary arterial hypertension treatment, Uptravi, threatening its position in a lucrative therapeutic area.

Should investors sell immediately? Or is it worth buying Johnson & Johnson?

Furthermore, the long-running litigation concerning the company’s talc-based consumer products continues to weigh on investor sentiment. Recent institutional selling activity has also signaled a degree of caution among major shareholders.

Financial Standing and Future Outlook

Johnson & Johnson remains a behemoth with a market capitalization of approximately $577.5 billion. The company reported fourth-quarter earnings of $2.46 per share on revenue of $24.28 billion. It continues to return capital to shareholders, with a quarterly dividend payout of $1.30 per share.

While the latest FDA successes bolster the long-term growth prospects of its pharmaceutical portfolio—a strategic imperative as patents expire in other divisions—the immediate investor focus appears to be on competitive dynamics and legacy legal issues. Forthcoming quarterly results will be scrutinized for signs that progress in the drug pipeline can ultimately outweigh these persistent doubts.